Research library
The research library
Every primary source behind a claim on this site, tier-graded for provenance and tagged for the strength of the evidence it carries.
- Sources indexed
- 221
- Peptides covered
- 44
- Tier 1 share
- 0%
- Matching filter
- 10
F·Filter
Reset allT2·Peer-secondary literature
Peer-reviewed reviews and cohort/observational work — context, not bedrock.
10 sources
- 2023Meta-analysisstrongn=1,773
Cerebrolysin for acute ischaemic stroke
Ziganshina LE, Abakumova T, Nurkhametova D, +1 · Cochrane Database of Systematic Reviews
The 2023 Cochrane review pooled seven trials and 1,773 participants and concluded with moderate-certainty evidence that Cerebrolysin probably has little to no effect on all-cause death after acute ischemic stroke — the load-bearing skeptical reading of the trial body.
- 2023Reviewstrong
Long COVID: major findings, mechanisms and recommendations
Davis HE, McCorkell L, Vogel JM, +1 · Nature Reviews Microbiology
At least 10% of SARS-CoV-2 infections produce a long-COVID syndrome, with more than 200 catalogued symptoms across multiple organ systems and an estimated 65 million affected globally — the cornerstone synthesis that consolidated the post-acute pathophysiology literature into a single mechanism framework.
- 2019Reviewstrong
Global Consensus Position Statement on the Use of Testosterone Therapy for Women
Davis SR, Baber R, Panay N, +13 · Climacteric
The ten-society global consensus narrows the testosterone-for-women indication to a single use case — postmenopausal HSDD — and explicitly recommends against compounded testosterone products at supraphysiologic dosing, the framework that anchors contemporary off-label prescribing under specialist supervision.
- 2019Meta-analysisstrong
The prevalence of sarcopenia in community-dwelling older adults, an exploration of differences between studies and within definitions: a systematic review and meta-analyses
Mayhew AJ, Amog K, Phillips S, +5 · Age and Ageing
Across 109 articles, 58 cohorts, and 26 countries, sarcopenia prevalence ranged from 9.9% to 40.4% depending on the diagnostic definition applied — a four-fold spread driven by methodology rather than biology.
- 2019Reviewstrong
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft AJ, Bahat G, Bauer J, +15 · Age and Ageing
EWGSOP2 demoted muscle mass from primary diagnostic criterion to confirmatory finding and put strength first — the conceptual reframing that explains why so many peptide trials report lean-mass gains that do not move the clinical endpoint.
- 2018Reviewstrong
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
Bhasin S, Brito JP, Cunningham GR, +7 · Journal of Clinical Endocrinology and Metabolism
The 2018 Endocrine Society guideline anchors the modern diagnosis: hypogonadism requires both unequivocally and consistently low morning total testosterone and symptoms or signs consistent with deficiency — biochemistry alone or symptoms alone do not qualify.
- 2015Reviewstrong
Ghrelin
Müller TD, Nogueiras R, Andermann ML, +9 · Molecular Metabolism
The 2015 multi-author Molecular Metabolism review that consolidated the ghrelin field — fifty co-authors spanning the major laboratories that built ghrelin pharmacology across two decades, covering the receptor, signaling, gastrointestinal and central effects, sleep-wake regulation, reward-seeking, and the pharmacological landscape of the secretagogue class.
- 2005Mechanisticstrong
Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog
Jetté L, Léger R, Thibaudeau K, +3 · Endocrinology
CJC-1295 was identified as the lead compound from a panel of three hGRF(1-29)-albumin bioconjugates — present in rat plasma beyond 72 hours and producing a fourfold increase in GH AUC versus unmodified hGRF(1-29). This is the molecule's origin story.
- 2004Mechanisticstrong
Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist
Pfaus JG, Shadiack A, Van Soest T, +2 · Proceedings of the National Academy of Sciences
PT-141 selectively increased appetitive sexual behaviors — solicitations and hops-and-darts — in ovariectomized female rats without affecting lordosis, pacing, locomotion, or place preference, the first pharmacological evidence that central melanocortin agonism modulates sexual desire specifically rather than reflexive sexual response.
- 1995Meta-analysisstrong
The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis
Lijesen GK, Theeuwen I, Assendelft WJ, +1 · British Journal of Clinical Pharmacology
A criteria-based meta-analysis of 24 HCG-for-obesity trials found that 11 of the 12 methodologically adequate studies reported no effect of HCG on weight loss, fat redistribution, hunger, or sense of well-being — the load-bearing negative result behind the modern medical consensus that the Simeons HCG diet does not work.